The latest price target for Cellectar Biosciences (NASDAQ:CLRB) was reported by Maxim Group on March 10, 2026. The analyst firm set a price target for $10.00 expecting CLRB to rise to within 12 months (a possible 270.37% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Cellectar Biosciences (NASDAQ:CLRB) was provided by Maxim Group, and Cellectar Biosciences upgraded their buy rating.

The last upgrade for Cellectar Biosciences Inc happened on March 10, 2026 when Maxim Group raised their price target to $10. Maxim Group previously had a hold for Cellectar Biosciences Inc.

The last downgrade for Cellectar Biosciences Inc happened on May 14, 2025 when Maxim Group changed their price target from N/A to N/A for Cellectar Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on March 10, 2026 so you should expect the next rating to be made available sometime around March 10, 2027.

While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a upgraded with a price target of $0.00 to $10.00. The current price Cellectar Biosciences (CLRB) is trading at is $2.70, which is within the analyst’s predicted range.